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A Major Determinant for Binding and Aminoacylation
of tRNAAla in Cytoplasmic Alanyl-tRNA Synthetase Is
Mutated in Dominant Axonal Charcot-Marie-Tooth Disease
Philippe Latour,1,* Christel Thauvin-Robinet,3 Chantal Baudelet-Me´ry,5 Pierre Soichot,4 Veronica Cusin,3
Laurence Faivre,3 Marie-Claire Locatelli,1 Martine Mayenc¸on,1 Annie Sarcey,1 Emmanuel Broussolle,2,6
William Camu,7 Albert David,8 and Robert Rousson1
Charcot-Marie-Tooth disease (CMT) is the most common cause of inherited peripheral neuropathy, with an estimated frequency of
1/2500. We studied a large family with 17 patients affected by the axonal form of CMT (CMT2). Analysis of the 15 genes or loci known
to date was negative. Genome-wide genotyping identiﬁed a CMT2 locus in 16q21-q23 between D16S3050 and D16S3106. The
maximum two-point LOD score was 4.77 at q ¼ 0 for marker D16S3050. Sequencing of candidate genes identiﬁed a unique mutation,
c.986G>A (p.Arg329His), affecting a totally conserved amino acid in the helical domain of cytoplasmic alanyl-tRNA synthetase (AlaRS).
A second family with the same mutation and a different founder was then identiﬁed in a cohort of 91 CMT2 families. Although mislo-
cation of mutant Arg329His-AlaRS in axons remains to be evaluated, experimental data point mostly to a quantitative reduction in
tRNAAla aminoacylation. Aminoacylation and editing functions closely cooperate in AlaRS, and Arg329His mutation could also lead
to qualitative errors participating in neurodegeneration. Our report documents in 18 patients the deleterious impact of a mutation in
human cytoplasmic AlaRS and broadens the spectrum of defects found in tRNA synthetases. Patients present with sensory-motor distal
degeneration secondary to predominant axonal neuropathy, slight demyelination, and no atypical or additional CNS features.Charcot-Marie-Tooth disease (CMT [MIM 118300]) is the
most common cause of inherited peripheral neuropathy,
with an estimated frequency estimated of 1/2500. CMT is
generally transmitted as a dominant trait and presents a
high genetic heterogeneity. Both motor and sensory
nerves are affected by a progressive distal degeneration,
but motor disability in patients is usually more prominent
than sensory disorders and is typically represented by
distal amyotrophy of legs and gait disturbances.1 Patients
can be classiﬁed by electromyographic examination as
having a demyelinating form (CMT1) with reduced nerve
conduction velocities (NCVs) or an axonal form (CMT2)
with conserved NCVs. A value of 38 m/s for the motor
NCV in the median nerve is most commonly used to sepa-
rate CMT1 and CMT2.2 Some families present values
between 25 and 45 m/s and are considered to have domi-
nant-intermediate forms of CMT (DI-CMT).3 Fifteen genes
or loci are known to date for dominant CMT2 or DI-CMT
(Table S1, available online) but mutations have not been
identiﬁed in most CMT2 families.4
We studied a large French family (family 1) that included
17 individuals affected with autosomal-dominant CMT2
and two unaffected but at-risk individuals (IV.1 and IV.8),
aged 50 and 30 yrs, respectively, ascertained by neurolog-
ical examination (Table 1). Mean age at onset was 28 yrs
(range: 6–54 yrs). All patients were ambulatory and
presented no pyramidal or cerebellar signs. One patient
(IV.7) used a wheelchair for occasional assistance only.1De´partement de Biochimie, Centre de Biologie Est, 2Service de Neurologie
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The AOne patient (IV.5) had severe asymmetric muscular
atrophy in the lower left limb (Figure 1). Electromyo-
graphic examination demonstrated a motor and sensory
denervation in all patients investigated. Mean motor
NCV in themedian nerve was 41m/s (range: 32.4–50m/s).
All patients gave their written consent to genetic investiga-
tions in accordance with French legislation.
As a typical case history, we describe the clinical ﬁndings
of patient IV.13 (family 1). The ﬁrst signs of the disease
were noticed by this female patient at the age of 25, during
her ﬁrst pregnancy. Symptoms consisted of mild to
moderatemotor disability of the lower right limb and occa-
sional motor disability of the right hand. Neurological
examination was ﬁrst performed when the patient was
30 yrs of age. Her gait was normal, with no ataxia, but
standing on the heels was difﬁcult for her. A bilateral distal
motor weakness in the lower limbs was noticed, with a
muscular force test score of 4/5 (normal score ¼ 5) for
the extensor digitorum brevis muscles. There was no
amyotrophy or foot deformation. Vibration sense was
mildly diminished in the right lower limb. Deep tendon
reﬂexes were weak at the knees and absent at the ankles.
Examination of the upper limbs was normal. There were
no tremor or pyramidal-tract signs, and no Argyll-Robert-
son pupil sign was observed. Motor NCVs were 43.4 m/s
on the right median nerve and 41.4 m/s on the left median
nerve (elbow-wrist), with reduced amplitudes, respectively,
of 15% and 11%. Right ulnar nerve motor NCV wasC, Hoˆpital Neurologique, Hospices Civils de Lyon, F-69500 Bron, France;
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Table 1. Clinical Features and Electroneuromyographic Data
Fam. ID
Age at
Onset
of First
Signs (Yrs)
First Signs
in LL
before
UL
First
Presenting
Features
Age at
Clinical
Exam
(Yrs)
Weakness
Dist.
Sensory
Loss
Dist.
Reflex
Loss Dist.
Use of
Walking
Stick
(Yrs)
Use of
Wheelchair
(Yrs)
ENMG:
Motor or
Sensory
Alteration
Motor NCV
Median
Nerve (m/s)
1 III.1 >50 þ Repeated ankle sprains 77 LL LL LL - - MS 32.4
1 III.3 50 þ LL weakness 71 LL LL LLþUL - - MS 35
1 III.5 15 ¼ Repeated ankle sprains 67 LLþUL LLþUL LLþUL - - MS 35.7
1 III.6 17 þ Walking difﬁculties 61 LLþUL LL LL 56 - MS NA
1 IV.1 AS AS AS 50 AS AS AS AS AS N
1 IV.2 54 þ Mild distal LL
amyotrophy
54 NA NA NA - - MS 45.7
1 IV.3 45 þ Foot deformation 47 NA NA NA - - MS 40.8
1 IV.4 45 ¼ Repeated ankle sprains 49 LLþUL LL LLþUL - - MS 50
1 IV.5 6 þ Repeated ankle sprains 54 LL LL LL - - MS 45
1 IV.7 26 þ Pain and LL weakness 38 LL - LLþUL 40 42 MS 44.5
1 IV.8 AS AS AS 30 AS AS AS AS AS N
1 IV.9 18 þ LL and hand weakness 32 LLþUL LLþUL LLþUL - - MS 36.5
1 IV.10 10 þ Repeated ankle sprains 30 LL LL LL - - MS NA
1 IV.11 25 þ Repeated ankle sprains 41 LL LL LLþUL - - MS 40.5
1 IV.12 NA þ LL weakness 41 LL LL LL - - MS NA
1 IV.13 25 ¼ LL weakness 32 LLþUL - LL - - MS 42.4
1 IV.16 22 þ Cramps in LL 34 LL LL LL - - MS 43.5
1 V.1 AS AS AS 9 AS AS AS AS AS MS 46
1 V.2 15 þ Repeated ankle sprains 28 LL LL LLþUL - - NA
2 II.1 14 þ Walking difﬁculties 32 LL LL LL - - MS 35–39
Abbreviations are as follows: AS, asymptomatic; Dist., distribution; ENMG, electroneuromyography; Fam., family; LL, lower limbs, M, pure motor, MS, motor and
sensory; N, normal; NA, not available; UL, upper limbs.47.5m/s, with normal amplitudes. SensoryNCVwas 50m/s
on the right radial nerve. Motor and sensory responses
were absent in the lower limbs (in popliteal nerves).
The patient is now 32 yrs old. Clinical ﬁndings are
unchanged.Figure 1. Patient IV.5 of Family 1
78 The American Journal of Human Genetics 86, 77–82, January 8, 20Sequencing of coding exons and linkage analysis were
negative for all CMT2 and DI-CMT genes known to date.
Twelve patients (III.1, IV.1, IV.2, IV.4, IV.7, IV.8, IV.9,
IV.10, IV.11, IV.12, IV.16, and V.2) were selected for SNP
genotyping. A genome-wide scan was performed with
the Affymetrix Genome-Wide Human SNP 6.0 Array.
A total of 889,406 SNPs were genotyped for each of the
patients studied, and a unique contig of 18 SNPs was found
to be coherent with transmission of the disease in 16q21-
q23 between SNPs rs16962499 and rs446695 (59.3 Mb
and 76.6Mb in NCBI build 36.3). Microsatellite haplotypes
for the whole family (Figure 2) showed closer recombina-
tions (patients III.5, IV.3, and IV.8) and reﬁned the new
CMT2 locus as being a region of 7.1 cM and 10.2 Mb
between markers D16S503 and D16S3018 (62.5 Mb–72.7
Mb in NCBI build 36.3). Amaximum two-point parametric
LOD score of 4.77 was observed at q ¼ 0 for marker
D16S3050 (Table S2).
In a cluster of ~130 expressed sequences or genes, the
following were considered candidate genes for CMT2 and
were sequenced: DYNC1LI2 (dynein cytoplasmic 1 light
intermediate chain 2 [MIM 611406], 65.3 Mb in NCBI10
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Figure 2. Pedigrees and Haplotypes
Filled symbols indicate affected individuals. Empty symbols indicate unaffected individuals. Identical alleles on the disease-causing
haplotypes are boxed for each family. Closest recombinants in family 1 are shown in red (centromeric side) or blue (telomeric side).build 36.3), HSF4 (heat shock transcription factor 4 [MIM
602438], 65.8 Mb), TPPP3 (tubulin polymerization-pro-
moting protein family member 3, noMIM entry, 66.0 Mb),
and AARS (cytoplasmic alanyl-tRNA synthetase [MIM
601065], 68.8 Mb). The lysyl-tRNA synthetase gene
(KARS [MIM 601421]) located at 74.2 Mb in 16q23 was
also sequenced, although it was excluded by recombina-
tion events. We identiﬁed only one missense mutation,
c.986G>A (p.Arg329His), in exon 8 of AARS (Figure S1).
All affected patients were found to be heterozygous for
the mutation, and all unaffected individuals showed a
normal sequence. An additional series of 91 dominant
and unrelated CMT2 cases were then analyzed. For these
cases, mutation screening had been unsuccessful in at least
MFN2 (MIM 608507), GJB1 (MIM 304040), andMPZ (MIM
159440). A second French family (family 2) was identiﬁed
as having the same c.986G>A mutation, which also co-
segregated with the disease. Microsatellite analysis demon-
strated a different founder for the two families (Figure 2).
The mutation was not found in 500 unrelated anonymous
DNA samples used as controls (1000 chromosomes).
Highly conserved and speciﬁc aminoacyl-tRNA synthe-
tases attach amino acids to their cognate tRNAs and areThe Akey enzymes for the exact translation of the genetic code
into proteins. A single G3:U70 base pair in its acceptor
armmarks tRNAAla for alanine charging by aminoacylation
in the catalytic site of alanyl-tRNA synthetase (AlaRS).5
Unlike almost all amino synthetases, AlaRS recognizes
tRNAAla uniquely by its acceptor arm and not by additional
determinants in the anticodon stem.5 Particularly chal-
lenging is the differentiation among alanine, serine, and
glycine in the catalytic domain, and, early in evolution,
AlaRSs integrated a modular editing domain to hydro-
lyse-mischarged tRNAAla.6–8 Aminoacylation and editing
domains closely cooperate and link to the acceptor arm
of the same tRNA, using both sides of the G3:U70 determi-
nant.9 Conservation of sequence and of modular organiza-
tion from E. coli to H. sapiens AlaRSs is one of the highest
observed among all synthetases.10 From the N teminal to
the C terminal, E. coli and H. sapiens AlaRS present an ami-
noacylation domain (AD), a middle helical domain (HD)
and an editing domain (ED)9,11 (Figure 3). In E. coli, a
so-called C-Ala domain is responsible for efﬁcient editing
by bringing together AD and ED12 (Figure 3). H. sapiens
AlaRS is monomeric10 or homodimeric13 and differs
mostly from E. coli AlaRS by its C-terminal sequencemerican Journal of Human Genetics 86, 77–82, January 8, 2010 79
Figure 3. Modular Organization of H. sapiens and E. coli AlaRS
Abbreviations are as follows: AD, aminoacylation domain; HD,
helical domain; ED, editing domain. In E. coli, the C-Ala domain
brings together AD and ED in docking models, and an N-terminal
fragment of 461 amino acids (ADþHD) is sufﬁcient for complete
and speciﬁc aminoacylation of tRNAAla.downstream ED. Human cytoplasmic and mitochondrial
AlaRS are encoded by two different nuclear genes, AARS
and AARS2 (MIM 612035), respectively.14 AARS is
composed of 21 exons and codes for 968 amino acids.
Primers and conditions for AARS sequencing are in
Table S3.
Arginine 329 is located in the middle helical domain of
H. sapiens AlaRS and is the ortholog of R314 in E. coli
(Figure 4). From crystal structure, it was deduced that
E. coli R314 directly interacts with the aromatic ring of
F366 (human F382) and has water-mediated interactions
with E362 (human E378) and G402 (human G419).11
The network composed of these four amino acids is strictly
conserved in Archeobacteria and Eubacteria,11 as well as
from E. coli to H. sapiens (Figure 4). Extensive mutagenesis
experiments demonstrated that among 37 conserved
candidate amino acids with side chains that are able to
mediate hydrogen-bound interactions in the E. coli AlaRS80 The American Journal of Human Genetics 86, 77–82, January 8, 20helical domain (Figure 4), D285 and R314 are the two
major determinants for binding and efﬁcient aminoacyla-
tion of tRNAAla.15 The R314A mutant shows a ~700-fold
reduction in aminoacylation as a result of a reduced
binding of tRNAAla by its acceptor arm in the catalytic
site. Mutants R314A and R314D were unable to comple-
ment AlaRS null strains, and the R314K mutant only
partially rescued cell growth.15
To our knowledge, no amino acid other than arginine
has been described in the three kingdoms of life as playing
the key role of R329 in the middle helical domain of AlaRS.
In two independent CMT2 families, we found a substitu-
tion of R329 by histidine. Arginine 329 is located in the
AlaRS a10 helix.8 In a helices, arginine and lysine side
chains have comparable properties and are signiﬁcantly
more ﬂexible than histidine side chain.16,17 Moreover, argi-
nine and lysine are strong proton acceptors, whereas histi-
dine is a variably protonated imidazole ring. Given that
even replacement of R314 by lysine is deleterious15 and
none of the adjacent arginines can correct a defect of the
fully conserved R314,15 we postulate that the R329H
substitution is deleterious in H. sapiens AlaRS. Crystallo-
graphic studies support the hypothesis that the deleterious
effect is likely to be related to modiﬁcations within the
strictly conserved network R329-E378-F382-G419.11
tRNA synthetase deﬁciencies have already been impli-
cated in neurological disorders such as leukoencephalop-
athy, spinal cord disturbances, and distal spinal muscular
atrophy.13 Rare CMT cases have been related to defects in
glycyl-tRNA synthetase18 (GlyRS [MIM 601472]) and in
tyrosyl-tRNA synthetase19 (TyrRS [MIM 608323]). Exact
roles of GlyRS and TyrRS mutants in CMT are still being
investigated.13 Among other possibilities, defective amino-
acylation and abnormal distribution in axons are postu-
lated for both GlyRS13,20 and TyrRS19 mutants. In ourFigure 4. Alignment of AlaRS Helical
Domains from E. coli to H. sapiens
GenBankaccess forproteinswereas follows:
NP_001596 (Homo sapiens), ACT28094
(Escherichia coli), NP_001093987 (Rattus
norvegicus), NP_001005836 (Gallus gallus),
NP_001037775 (Danio rerio), and
AAF05593 (Drosophila melanogaster). Fully
conserved amino acids are indicated with
an asterisk (*) below the alignment. Arrow-
heads (;) on top of the alignment indicate
amino acids that have been studied by
mutagenesis.15 E. coli D285 and R314
(H. sapiens D300, and R329) are indicated
in yellow. E. coli R314 interacts with E362,
F366, and G402, shown in blue (H. sapiens
E378, F382, and G419).
10
observation, functional assays strongly suggest a modiﬁed
afﬁnity for tRNAAla and a reduced aminoacylation efﬁ-
ciency.15 However, ﬁndings in GlyRS and TyrRS indicate
that aminoacylation function could be differentially
affected by CMT-causing mutations and therefore might
not be a major determinant in the disease.13 Thus, addi-
tional functional studies are necessary to analyze loss of
function or neuron-speciﬁc effects resulting from a
R329Hmutation. The hypothesis of a deleterious mislocal-
ization of mutant R329H AlaRS in axons remains to be
evaluated. Charging errors could also be considered,
because defective binding of the tRNAAla acceptor arm in
the catalytic site for R314 and R329 mutants15 could
modify the cooperation between aminoacylation and edit-
ing. A mouse model showed that a homozygous defect in
AlaRS editing is responsible for mischarging of tRNAAla
with serine or glycine and leads to protein misfolding
and neurodegeneration, indicating that AlaRS ﬁdelity
errors are sufﬁcient for neurodegeneration.21 R314A-AlaRS
also has a residual binding of tRNAAla that is not distin-
guishable from a nonspeciﬁc background of tRNALys
binding,15 suggesting that binding of noncognate tRNAs
could be another source of qualitative errors for R314
and R329 mutants.
We identiﬁed two unrelated families with the same
amino acid variation. Because direct neurological exami-
nation in family 2 was limited to proband II.1, interfa-
milial comparison was difﬁcult to establish. Nonetheless,
clinical ﬁndings for the family 2 proband were similar to
those found in several age-matched patients of family 1
(IV.10, IV.12, and IV.16), and identical age at onset
together with analogous slight demyelinating signs for
the same duration of disease were found in patient IV.9.
Monozygous twins III.1 and III.2 are both reported as
having only mild motor trouble in the feet and Achilles’
tendons areﬂexia at the age of 13 yrs, which ﬁts well
with a disease limited mainly to the lower limbs, as illus-
trated by family 1. The R329Hmutation occurred indepen-
dently in the two families, indicating that dinucleotide CG
in codon 329 could be a mutational hotspot and that data
on other families with the same mutation might allow
additional interfamilial comparisons. In both families,
patients with the Arg329His AlaRS mutation present
with sensory-motor distal degeneration secondary to
predominant axonal neuropathy and with absent or slight
demyelination. Neurodegeneration implicated peripheral
nerves with no evident brainstem or spinal cord involve-
ment. Asymmetric amyotrophy is found in one out of
the 18 cases reported here but is also observed in 10%–
15% of CMT2 patients.4 Distal degeneration of peripheral
motor nerves is by now a common phenotypic feature
related to mutations in human amino synthetases. Data
from additional families would help to conﬁrm and delin-
eate involvement of cytoplasmic AlaRS mutations in CMT
or in other neurodegenerative disorders. Other tRNA
synthetase genes could be good candidates for other
subtypes of CMT disease.The ASupplemental Data
Supplemental Data include one ﬁgure and three tables and can be
found with this article online at http://www.ajhg.org.Acknowledgments
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